180 related articles for article (PubMed ID: 37160318)
21. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer.
Ikeuchi N; Igata F; Kinoshita E; Kawabata T; Tan I; Osaki Y; Otsuka R; On R; Ikeda T; Nakao A; Sasaki T; Aoyama T; Hirano R; Harada T; Ebi N; Fujita M; Inoue H
Anticancer Res; 2023 Feb; 43(2):713-724. PubMed ID: 36697078
[TBL] [Abstract][Full Text] [Related]
22. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Seto T; Nosaki K; Shimokawa M; Toyozawa R; Sugawara S; Hayashi H; Murakami H; Kato T; Niho S; Saka H; Oki M; Yoshioka H; Okamoto I; Daga H; Azuma K; Tanaka H; Nishino K; Tohnai R; Yamamoto N; Nakagawa K
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105689
[TBL] [Abstract][Full Text] [Related]
24. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with
Reck M; Shankar G; Lee A; Coleman S; McCleland M; Papadimitrakopoulou VA; Socinski MA; Sandler A
Expert Rev Respir Med; 2020 Feb; 14(2):125-136. PubMed ID: 31829747
[No Abstract] [Full Text] [Related]
25. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
27. A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.
Ardeshir-Larijani F; Althouse SK; Leal T; Feldman LE; Hejleh TA; Patel M; Gentzler RD; Miller AR; Hanna NH
Clin Lung Cancer; 2022 Nov; 23(7):578-584. PubMed ID: 36041949
[TBL] [Abstract][Full Text] [Related]
28. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA
J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807
[TBL] [Abstract][Full Text] [Related]
29. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first-line therapy in adenocarcinoma patients.
Wang M; Li J; Xu S; Li Y; Li J; Yu J; Tang X; Zhu H
Cancer Med; 2023 Mar; 12(5):5352-5363. PubMed ID: 36271595
[TBL] [Abstract][Full Text] [Related]
31. A case of the third-line treatment of lung adenocarcinoma using nivolumab combined with anlotinib.
Yang Y; Li J; Yu P; Ge J; Liu B; Li J
Pharmazie; 2021 Jul; 76(7):338-340. PubMed ID: 34256897
[TBL] [Abstract][Full Text] [Related]
32. Optimal Treatments for NSCLC Patients Harboring Primary or Acquired
Sun D; Tao J; Yan W; Zhu J; Zhou H; Sheng Y; Xue C; Li H; Hou H
Technol Cancer Res Treat; 2022; 21():15330338221128414. PubMed ID: 36148917
[No Abstract] [Full Text] [Related]
33. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
34. Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy.
He H; Yang W; Huang Y; Zhang X; Peng Y; Yang Z
Angiogenesis; 2022 Feb; 25(1):5-8. PubMed ID: 34342748
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
37. Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
Gauvin C; Krishnan V; Kaci I; Tran-Thanh D; Bédard K; Albadine R; Leduc C; Gaboury L; Blais N; Tehfe M; Routy B; Florescu M
Curr Oncol; 2021 Jan; 28(1):593-605. PubMed ID: 33498159
[TBL] [Abstract][Full Text] [Related]
38. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
Isla D; de Castro J; García-Campelo R; Lianes P; Felip E; Garrido P; Paz-Ares L; Trigo JM
Clin Transl Oncol; 2020 May; 22(5):759-771. PubMed ID: 31368078
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Rojkó L; Reiniger L; Téglási V; Fábián K; Pipek O; Vágvölgyi A; Agócs L; Fillinger J; Kajdácsi Z; Tímár J; Döme B; Szállási Z; Moldvay J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1219-1226. PubMed ID: 29675791
[TBL] [Abstract][Full Text] [Related]
40. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]